Studies on receptor binding and signal transduction pathways of unoprostone isopropyl

Journal of Ocular Pharmacology and Therapeutics

Volumn 17, Issue 5, 2001, Pages 433-441

  Bhattacherjee, P ^a   Paterson, C A ^a   Percicot, C ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 17 PHENYLTRINORPROSTAGLANDIN E1; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; BEHENIC ACID; BUTAPROST; CALCIUM ION; CYCLIC AMP; DRUG METABOLITE; FLUPROSTENOL; ILOPROST; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN EP1 RECEPTOR; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN FP RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SULPROSTONE; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CATTLE; CELL MEMBRANE; CILIARY BODY; CILIARY MUSCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS LUTEUM; DRUG RECEPTOR BINDING; IRIS; LIGAND BINDING; LUTEAL CELL; NONHUMAN; RABBIT; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; CALCIUM; CATTLE; CILIARY BODY; CORPUS LUTEUM; CYCLIC AMP; DINOPROST; FEMALE; IRIS; LIGANDS; MUSCLE, SMOOTH; RABBITS; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 0035202802     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076801753266811     Document Type: Article

References (41)

1. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina
2. The metabolism of omega-3 polyunsaturated fatty acid in the eye: The possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology
3. Tissue levels of PUFA during early human development
4. Detection of retinal lipid hydroperoxides in experimental uveitis
5. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3): Role of phosphatidylserine in antiapoptotic effect
6. Polyunsaturated fatty acids are potent neuroprotectors
7. The role of docosahexaenoic acid (22:6n-3) in neuronal signalling
8. Docosahexaenoic acid promotes differentiation of developing photoreceptors in culture
9. Docosahexaenoic acid is required for the survival of rat retinal photoreceptors in vivo
10. Docosahexaenoic acid is a major n-3 polyunsaturated fatty acid in bovine retinal microvessels
11. The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals
12. Effects of tear secretion of isopropyl unoprostone eye drops in rabbits
13. Long-term study of UF-021 (Rescula) ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension
14. Long-term clinical effect of isopropyl unoprostone in normal-tension glaucoma
15. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure
16. Effect of UF-021 on optic nerve head circulation in rabbits
17. Effect of isopropyl unoprostone on choroidal circulation - Changes in choroidal blood flow and intraocular pressure with topical application
18. Photoreceptor protection from constant light-induced damage by isopropyl unoprostone, a prostaglandin F2alpha and metabolite-related compound
19. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers
20. Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds
21. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension
22. Initial clinical studies with prostaglandins and their analogues
23. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on the intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomised, double-masked comparison with timolol 0.5%
24. Latanoprost-induced iris color darkening: A case report with long-term follow-up
25. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue
26. Latanoprost 0.005% and anterior segment uveitis
27. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
28. Increased iris pigment in a child due to latanoprost
29. Evidence of early change in iris color with latanoprost use
30. Prostaglandin-induced iris color darkening. An experimental model
31. Prostaglandin F2 alpha receptors in the human trabecular meshwork
32. Prostaglandin derivatives as ocular hypotensive agents
33. Protein measurement with the folin phenol reagent
34. 2+ mobilization in nontransformed ciliary nonpigmented epithelial cells
35. 2+ indication with greatly improved fluorescence properties
36. The presence of gonadotropin and prostaglandin E receptors in the cell membranes of bovine corpora lutea throughout pregnancy
37. Prostaglandin E and F2alpha receptors in bovine corpora lutea: Relative affinities of products of arachidonic acid metabolism by cyclo-oxygenase
38. Selected properties of [3H]-prostaglandin E1 binding to dispersed bovine luteal cells
39. Pharmacology of [3H] prostaglandin E1/[3H] prostaglandin E2 and [3H] prostaglandin F2 alpha binding to EP3 and FP receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data
40. Pharmacological characterization of prostaglandin-related ocular hypotensive agents
41. Prostaglandin receptors coupled to adenylyl cyclase in the iris-ciliary body of rabbits, cats and cows